Alpharetroviral Self-inactivating Vectors: Long-term Transgene Expression in Murine Hematopoietic Cells and Low Genotoxicity-Reference-Cited by-同舟云学术

Alpharetroviral Self-inactivating Vectors: Long-term Transgene Expression in Murine Hematopoietic Cells and Low Genotoxicity

Published:2012-05 Issue:5 Volume:20 Page:1022-1032
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Suerth Julia D,Maetzig Tobias,Brugman Martijn H,Heinz Niels,Appelt Jens-Uwe,Kaufmann Kerstin B,Schmidt Manfred,Grez Manuel,Modlich Ute,Baum Christopher,Schambach Axel

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference49 articles.

1. Update on gene therapy for immunodeficiencies;Kohn;Clin Immunol,2010

2. Transcription start regions in the human genome are favored targets for MLV integration;Wu;Science,2003

3. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells;Hematti;PLoS Biol,2004

4. HIV-1 integration in the human genome favors active genes and local hotspots;Schröder;Cell,2002

5. Hot spots of retroviral integration in human CD34+ hematopoietic cells;Cattoglio;Blood,2007

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alpharetroviral Vector–Mediated Gene Therapy for IL7RA-Deficient Severe Combined Immunodeficiency;Human Gene Therapy;2024-08-27

2. Long Terminal Repeats of Gammaretroviruses Retain Stable Expression After Integration Retargeting or Knock-In into the Restrictive Chromatin of Lamina-Associated Domains;2024-05-31

3. Retrovirale Vektoren – Effiziente Gentaxis für unterschiedliche Gentherapien;Gen- und Zelltherapie 2.023 - Forschung, klinische Anwendung und Gesellschaft;2023-12-30

4. Determinants of Retroviral Integration and Implications for Gene Therapeutic MLV—Based Vectors and for a Cure for HIV-1 Infection;Viruses;2022-12-21

5. Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy;Molecular Therapy - Oncolytics;2022-12